A. Daniyal Siddiqui, MD
Chief, Division Of Hematology, Medical Oncology (Cancer Medicine and Blood disorders)
- Director Quality and Safety Saint Vincent Cancer and Wellness Center
- Assistant Professor of Medicine at University of Massachusetts Medical School
Dr. Siddiqui is board certified in Internal Medicine, Hematology and Medical Oncology. As a hematologist/oncologist, Dr. Siddiqui treats many different types of cancers including but not limited to skin cancers (melanoma), Breast cancer, Lung cancer, gastrointestinal cancer, Lymphoma, Head and Neck cancer, Prostate, bladder, kidney, and uterine cancers. Dr. Siddiqui also treats benign and malignant Hematological diseases.
Dr. Siddiqui is confident that in the years ahead, cancer therapies will continue to improve. “Even though we have come a long way, there is still much to be done. We have many great treatments for early stage cancers, but we are still not talking about cures in advanced or stage IV cancers. However, it’s a very exciting time to be practicing in this field because its changing every day.”
Dr. Siddiqui is a big believer in communication and enjoys keeping a white board in his exam room so he can diagram things for patients to help them better understand their disease and treatment. “The patients find it very helpful because the visuals help them grasp the information more readily. I think the more patients know about their disease and what to expect, the better for everyone involved.”
- M.B., B.S. Nishtar Medical College, Multan-Pakistan 1987-1993
- M.D. 1995
- Fellow of College of Physicians and Surgeons Pakistan (FCPS-1), General Surgery 1995
- Fellowship in Hematology/Oncology, University of Massachusetts Medical School 2006-2009
- Residency, Internal Medicine, New York Medical College, Metropolitan Hospital, New York NY 2003-2006
- Research Fellow, Department of Medicine, Division of Hematology/Oncology at Westchester Medical Center, New York Medical College, Valhalla, NY 2000-2003
CERTIFICATIONS AND LICENSURE
- Diplomate, American Board of Hematology
- Diplomate, American Board of Medical Oncology
- Diplomate, American Board of Internal Medicine
- Massachusetts License
- Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: A marker of resistance to EGFR-1 therapy. Ann Surg Oncol 2010; 17:1168-76.
- Seiter K, Liu D, Loughran T, Siddiqui AD, Baskind P, Ahmed T. Phase I study of Temozolomide in Relapsed/Refractory Acute Leukemia. J of Clin Onc 2002:20;33249-3253.
- Siddiqui A, Sheikh ZS, Liu D, Seiter K. Coexistence of Inversion 16 and the PhiladelphiaChromosone in patients with AML. Leukemia & Lymphoma 2002:43;1137-1140.
- Seiter K, Liu D, Feldman E, Siddiqui AD, Hoang A, Baskind P, Ahmed T. Intravenous bolus topotecan in patients with AML. Leukemia & Lymphoma 2001:42;963-8.
- Seiter K, Lou D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I Study of Temozolomide in relapsed/refractory acute leukemias. 2001 Blood: Supp 2.
- Seiter K, Liu D, Lerner RG, Siddiqui AD, Kanchelia R, Ahmed T. Phase II study of Temozolomide in advanced MDS. Blood 2001: Supp. 2.
- Liu D, Seiter R, Kancheria R, Siddiqui AD, Ahmed T. Mitoxantrone, Ara C and Pentostatin: A Novel Non-myeloablative conditioning regimen (MAP regimen) for hematological malignancies. ASBMT 2002; Abstract #65.
- Seiter K, Liu, Loughran T, Siddiqui D, Kancherla R, Ahmed T. Temozolomide is an oral alkylating agent approved for treatment of Gliomas. In vitro studies demonstrate activity in acute leukemia. 2001; ASCO.
- Seikh ZS, Siddiqui A. “A Case of Carcinoma of penis metastatic to the pericardium. ”Case report for the American College of Physicians downstate annual competition.
- Siddiqui AD. Alzheimer’s disease “The price to pay for a longer life.” DAWN daily newspaper, June 14, 2000.